RxSight, Inc.
For the period ended Apr 25, 2024. Filed Apr 25, 2024.
View on SEC.govAbout this filing
What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.
Apr 25, 2024 · Filed Apr 25, 2024
Contents
Summary Compensation Table
| Non-Equity | ||||||
|---|---|---|---|---|---|---|
| Name and Principal Position (1) | Year | Salary ($) | Option Awards ($)(2) | Incentive Plan Compensation ($)(3) | All Other Compensation ($)(4) | Total Compensation ($) |
| Ron Kurtz, M.D | 2023 | 633,333 | 1,873,660 | 570,000 | 4,604 | 3,081,597 |
| Chief Executive Officer and President, Director | 2022 | 562,500 | — | 457,566 | 5,405 | 1,025,471 |
| Shelley Thunen | 2023 | 454,167 | 1,124,196 | 295,208 | 12,848 | 1,886,419 |
| Chief Financial Officer | 2022 | 416,667 | — | 223,667 | 11,021 | 651,355 |
| Eric Weinberg | 2023 | 454,167 | 889,989 | 295,208 | 13,364 | 1,652,728 |
| Chief Commercial Officer | 2022 | 416,667 | — | 214,042 | 8,188 | 638,897 |
| Ilya Goldshleger, Ph.D. | 2023 | 454,167 | 1,124,196 | 295,208 | 12,083 | 1,885,654 |
| Chief Operating Officer | 2022 | 416,667 | — | 219,313 | 21,833 | 657,813 |
(1)
RxSight has four named executive officers, each with corporate decision making authority. We have elected to provide compensation information for all four of them even though, due to transitional relief applicable to losing smaller reporting company status as of December 31, 2023 (on which we are relying for this proxy statement), we are only required by SEC rules to disclose compensation for three named executive officers.
(2)
These figures reflect the aggregate grant date fair value of stock option awards (service-based) granted in the fiscal year, computed in accordance with the provisions of Financial Accounting Standards Board (“FASB”) Accounting Standards Codification ASC 718, Compensation—Stock Compensation — Topic 718. See Note 9 to our financial statements for the year ended December 31, 2023 included in our Annual Report on Form 10-K for the year ended December 31, 2023 for a discussion of the assumptions made by us in determining the grant date fair value of our equity awards. With respect to stock option awards, the named executive officers will only realize compensation to the extent the trading price of our common stock is greater than the exercise price of such stock options.
(3)
The bonus amounts listed in this column reflect annual discretionary bonuses, based on performance in 2022 and 2023. The 2023 amounts disclosed represent a bonus under our 2023 bonus plan based upon the achievement of company objectives for the year ended December 31, 2023, which were paid in the first quarter of 2024. Our bonus plans are more fully described below under the section titled “2023 Bonus Plan”.
(4)
Includes 401(k) matching contributions and with respect to Dr. Goldshleger, an inventor bonus of $3,000 for 2023 and $13,500 for 2022.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.